Epana Biosciences
Biotechnology company building a first-in-class platform to transform the treatment of autoimmune disease using AI-driven insights to develop precision T-cell engagers targeting novel targets.
Notes
Epana Biosciences is a biotechnology company developing a first-in-class platform for the treatment of autoimmune diseases. The company leverages artificial intelligence and computational biology to identify novel targets and develop precision T-cell engagers.
T-cell engagers represent an emerging modality in autoimmune disease treatment, with the potential to selectively modulate immune responses implicated in autoimmunity. Epana's AI-driven approach aims to identify optimal targets and design molecules that can precisely engage T cells to restore immune tolerance.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Focus on autoimmune disease treatment
- AI-driven target identification
- Precision T-cell engager platform
- Novel target biology approach
- First-in-class therapeutic modality
Sources
- Company information pending further verification
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |